Peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections

Torriani, F.J.
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p11
Academic Journal
The article reports that peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. In patients with concurrent HIV and chronic hepatitis C virus infections, peginterferon X-2a plus ribavirin was more effective than peginterferon OC-2a plus placebo, and peginterferon X-2a plus placebo was more effective than interferon OC-2a plus ribavirin for inducing a sustained hepatitis C virologie response.


Related Articles

  • Virological response reduces mortality in HIV/hepatitis C coinfection. Levitan, Dave // Infectious Disease News;Apr2008, Vol. 21 Issue 4, p28 

    The article discusses research on the association between sustained virological response (SVR) to interferon plus ribavirin and reduction in liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. It references a study by J. Berenguer et al, presented at...

  • Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon α -- hype or hope? Vogel, Wolfgang // Wiener Klinische Wochenschrift;2004, Vol. 116 Issue 15/16, p508 

    Comments on the response of chronic hepatitis C patients to combination therapy with ribavirin and interferon. Administration of ribavirin and interferon; Prevalence of chronic hepatitis C; Benefits of the combination therapy for patients with chronic C patients.

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment. Jain, Mamta K.; He-Jun Yuan; Adams-Huet, Beverley; Reeck, Amanda; Shelton, Janel; Attar, Nahid; Song Zhang; Neumann, Avidan U.; Carney, David S.; Gale, Jr., Michael; William M. Lee // Journal of Infectious Diseases;9/15/2009, Vol. 200 Issue 6, p866 

    Background. Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection.We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein....

  • Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. Poordad, Fred; Reddy, K. Rajender; Martin, Paul // Clinical Infectious Diseases;1/1/2008, Vol. 46 Issue 1, p78 

    Background. Rapid virologic response (RVR), defined as an undetectable serum hepatitis C virus (HCV) RNA level at week 4 of treatment, is emerging as an important milestone in the treatment of patients who have chronic hepatitis C by use of pegylated interferon-alfa and ribavirin—the...

  • Therapeutical Aspects and Outcome of HIV/HCV Coinfected Patients Treated with Pegylated Interferon plus Ribavirin in an Italian Cohort. Righi, E.; Beltrame, A.; Bassetti, M.; Lindstrom, V.; Mazzarello, G.; Dentone, C.; Biagio, A.; Ratto, S.; Viscoli, C. // Infection;Aug2008, Vol. 36 Issue 4, p358 

    One-third of HIV-infected individuals suffer from chronic hepatitis C virus infection (HCV) in Europe. Recommendations from HCV–HIV International Panel advise current treatment with pegylated interferon plus ribavirin. We assessed the impact of interferon and ribavirin combination in 43...

  • Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. Fried, Michael W.; Shiffman, Mitchell L.; Reddy, K. Rajender; Smith, Coleman; Marinos, George; Gonçales, Fernando L.; Häussinger, Dieter; Diago, Moises; Carosi, Giampiero; Dhumeaux, Daniel; Craxi, Antonio; Lin, Amy; Hoffman, Joseph; Yu, Jian // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p975 

    Background: Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin,...

  • Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Schvoerer, Evelyne; Moenne-Loccoz, Rémy; Murray, John M.; Velay, Aurélie; Turek, Marine; Fofana, Isabel; Fafi-Kremer, Samira; Erba, Anne-Claire; Habersetzer, François; Doffoël, Michel; Gut, Jean-Pierre; Donlin, Maureen J.; Tavis, John E.; Zeisel, Mirjam B.; Stoll-Keller, Françoise; Baumert, Thomas F. // Journal of Infectious Diseases;Apr2013, Vol. 207 Issue 8, p1306 

    Background. A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape.Methods. We used a...

  • Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation. Panigrahi, Rajesh; Hazari, Sidhartha; Chandra, Sruti; Chandra, Partha K.; Datta, Sibnarayan; Kurt, Ramazan; Cameron, Craig E.; Huang, Zhuhui; Zhang, Haitao; Garry, Robert F.; Balart, Luis A.; Dash, Srikanta // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Purpose:Although chronic hepatitis C virus (HCV) infection has been treated with the combination of interferon alpha (IFN-α) and ribavirin (RBV) for over a decade, the mechanism of antiviral synergy is not well understood. We aimed to determine the synergistic antiviral mechanisms of IFN-α...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics